TABLE 4.
Clinical and Economic Outcomes
| Outcome | Rifaximin + Lactulose | Placebo + Lactulose | Difference |
|---|---|---|---|
| Clinical outcomes | |||
| QALYs per patient, discounted (undiscounted) | 6.4 (8.9) | 3.1 (4.1) | 3.3 (4.9) |
| LYs per patient, discounted (undiscounted) | 6.7 (9.4) | 3.2 (4.3) | 3.5 (5.1) |
| Number of liver transplantations (per 100) | 20 | 9 | 11 |
| Costs, $ | |||
| Drug costs | 84,521 | 664 | 83,857 |
| Other direct costs | 67,885 | 55,367 | 12,518 |
| Hospitalizations | 34,036 | 39,316 | –5,280 |
| HE-related | 22,469 | 26,257 | –3,789 |
| Non-HE-related | 11,568 | 13,059 | –1,491 |
| Liver transplantation | 33,849 | 16,051 | 17,798 |
| Total | 152,406 | 56,031 | 96,375 |
HE = hepatic encephalopathy; LY = life-year; QALY = quality-adjusted life-year.